Get the Stockscreener App
7.06
3.22%
0.22
After Hours:
7.04
-0.02
-0.28%
Candel Therapeutics Inc stock is traded at $7.06, with a volume of 944.80K.
It is up +3.22% in the last 24 hours and down -18.19% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$6.84
Open:
$6.72
24h Volume:
944.80K
Relative Volume:
0.27
Market Cap:
$300.43M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-4.1775
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-8.19%
1M Performance:
-18.19%
6M Performance:
+7.79%
1Y Performance:
+434.85%
1-Day Range:
$6.63
$7.2692
1-Week Range:
$6.45
$7.61
52-Week Range:
$1.16
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
7.06 | 300.43M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.73 | 110.00B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.64 | 74.82B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
652.19 | 38.43B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.54 | 34.12B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.12 | 27.56B | 3.30B | -501.07M | 1.03B | -2.1146 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
Candel Therapeutics Inc Stock (CADL) Latest News
How to Take Advantage of moves in (CADL) - Stock Traders Daily
Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock - MarketBeat
Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment - Yahoo Finance
Candel Therapeutics (NASDAQ:CADL) versus INmune Bio (NASDAQ:INMB) Head-To-Head Review - Defense World
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Drops By 33.0% - MarketBeat
Candel Therapeutics provides corporate update, highlights momentum - TipRanks
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission - Proactive Investors USA
Candel Therapeutics Highlights Pipeline Progress and Stability - TipRanks
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 - The Manila Times
Candel therapeutics CMO sells $88,749 in stock By Investing.com - Investing.com Australia
Where are the Opportunities in (CADL) - Stock Traders Daily
Candel therapeutics CMO sells $88,749 in stock - Investing.com India
Candel Therapeutics CTO sells shares worth $119,533 By Investing.com - Investing.com Australia
Candel therapeutics chief scientific officer sells $112,367 in stock By Investing.com - Investing.com Canada
Candel therapeutics chief scientific officer sells $112,367 in stock - Investing.com India
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock - MarketBeat
Candel Therapeutics CEO sells shares worth $173,995 By Investing.com - Investing.com Canada
Candel Therapeutics CTO sells shares worth $119,533 - Investing.com India
Candel Therapeutics interim CFO Charles Schoch sells $81,943 in stock By Investing.com - Investing.com Canada
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win - PharmaVoice
Candel Therapeutics’ $92 Million Common Stock Offering - Global Legal Chronicle
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Nasdaq
How Is The Market Feeling About Candel Therapeutics? - Benzinga
Barclays PLC Boosts Stock Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Geode Capital Management LLC Buys 51,111 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Institutions profited after Candel Therapeutics, Inc.'s (NASDAQ:CADL) market cap rose US$41m last week but retail investors profited the most - Simply Wall St
Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024 - MSN
When the Price of (CADL) Talks, People Listen - Stock Traders Daily
State Street Corp Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
MML Investors Services LLC Sells 51,063 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 109.6% in December - MarketBeat
Largest borrow rate increases among liquid names - TipRanks
6,573 Shares in Candel Therapeutics, Inc. (NASDAQ:CADL) Acquired by Fmr LLC - Defense World
Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive financial news
Research Analysts Set Expectations for CADL FY2024 Earnings - Defense World
Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch
Candel Therapeutics rides high on promising Phase 3 data, funding boost - Proactive Investors UK
Candel Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Insider Buying: Candel Therapeutics, Inc. (NASDAQ:CADL) Director Purchases 1,250,000 Shares of Stock - MarketBeat
Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial - Investing.com Australia
Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial By Investing.com - Investing.com South Africa
Candel Therapeutics aims to transform cancer outcomes - Proactive financial news
HC Wainwright Reiterates Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Candel Therapeutics Raises $92M in Oversubscribed Public Offering to Advance Cancer Drug Development - StockTitan
Candel Therapeutics raises $92M in public offering following prostate cancer trial success - Proactive Investors USA
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu | Chief Technology Officer |
Jan 15 '25 |
Sale |
7.22 |
14,322 |
103,476 |
96,790 |
| Schoch Charles | See Remarks |
Jan 15 '25 |
Sale |
7.22 |
9,511 |
68,717 |
43,038 |
| Tak Paul Peter | Chief Executive Officer |
Jan 15 '25 |
Sale |
7.22 |
21,704 |
156,811 |
251,912 |
| Nichols William Garrett | Chief Medical Officer |
Jan 15 '25 |
Sale |
7.22 |
10,428 |
75,342 |
79,320 |
0.78%
10.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):